TrialHeart and vessels2015

Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial.

Marian Christoph et al.PubMed ↗Publisher ↗

No numbers read from the abstract.